Live Breaking News & Updates on Innovative Field Solutions At Xcenda

In Partnership With AmerisourceBergen
|
Apr 26, 2021 10:00am
Rare diseases impact about 25 million people in the United States. The vast majority of rare diseases have no effective treatment, creating an urgent need for more research and development in this space. While there is a growing number of therapies in development for rare and ultra-rare conditions, manufacturers developing these products face unique challenges throughout the patient and product journey.
AmerisourceBergen, a global healthcare company, has provided commercialization services for more than 100 rare disease products.  
Rebecca Willumson, Publisher of Fierce Biotech, spoke with Teri Burnell, SVP of Innovative Field Solutions at Xcenda, and Susan Weidner, SVP of IntrinsiQ Analytics, both a part of AmerisourceBergen, about market access and commercialization strategies manufacturers need to consider in order to drive product success and patient access. ....

United States , Teri Burnell , Rebecca Willumson , Xcenda Formularydecisions , Susan Weidner , Innovative Field Solutions At Xcenda , Innovative Field Solutions As Rebecca , Advanceiq Network , Fierce Biotech , Innovative Field Solutions , Intrinsiq Analytics , Him Rebecca , Senior Vice President , Im Susan Weidner , Orphan Drug Act , ஒன்றுபட்டது மாநிலங்களில் , கடுமையான பயோடெக் , இம் ரிபேக்க , மூத்தவர் துணை ப்ரெஸிடெஂட் , ஆர்ஃபந் மருந்து நாடகம் ,